Since expression of IL-6 has been considered a predictor of mortality, it also act as a pharmacological target, tocilizumab (TCZ) has already been studied in clinical trials in an effort to treat patients with severe COVID-19 by neutralizing these key inflammatory mediators [87,144,146,147,148,149]. Here, IL6 is linked to COVID-19.